Technology
Health
Medical

CorMedix

$1.62
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (2.53%) Pre-Market
+$0.04 (2.53%) Pre-Market

Why Robinhood?

You can buy or sell CorMedix and other stocks, options, ETFs, and crypto commission-free!

About

CorMedix, Inc. operates as a pharmaceutical and medical device company, which seeks to in-license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. Read More The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.

Employees
22
Headquarters
Berkeley Heights, New Jersey
Founded
2006
Market Cap
172.02M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
3.01M
High Today
$1.67
Low Today
$1.57
Open Price
$1.66
Volume
1.09M
52 Week High
$2.74
52 Week Low
$0.1721

Collections

Technology
Health
Medical
Pharmaceutical
US
North America

News

Seeking AlphaMar 14

CorMedix Inc. (CRMD) CEO Khoso Baluch on Q4 2018 Results - Earnings Call Transcript

CorMedix Inc. (NYSEMKT:CRMD) Q4 2018 Results Conference Call March 14, 2019 4:30 PM ET Company Participants Daniel Ferry - IR LifeSci Advisors Khoso Baluch - CEO Bob Cook - CFO Liz Masson - EVP and Head of Clinical Operations Paul Chew - Chief Medical Officer Conference Call Participants Ram Selvaraju - H.C. Wainwright Jerry Isaacson - ROTH Capital Operator Greetings, and welcome to CorMedix Fourth Quarter 2018 Conference Call. At this time, all participants are in a listen-only mode. A question-...

853
Yahoo FinanceMar 11

Will CorMedix (CRMD) Report Negative Q4 Earnings? What You Should Know

CorMedix (CRMD) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

2,633
MarketBeatMar 2

Stock Price, News, & Analysis for CorMedix

CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/inten...

84

Earnings

-$0.17
-$0.11
-$0.04
$0.02
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.08 per share
Actual
$0.02 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.